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Editorial
In a continuing endeavor to recognize outstanding contri-
butions in the field of translational medicine, the Edito-
rial Board of the Journal of Translational Medicine (JTM)
established "The Excellence in Translational Medicine
Award" in 2006 [1]. With the thought to also recognize
excellent studies, defined as those exclusively based on the
study of human subjects, the Editorial Board has further
established "The Bedside-to-Bench Award" in 2008 [2].
The recipient of "The Excellence in Translational Medicine
Award" will receive a $4,000 prize, (of which $1,500 is
sponsored by Pfizer Global Research and Development and
Global Translational Medicine and $2,500 contributed
anonymously). The recipient of "The Bedside-to-Bench
Award" will receive $5,000, generously provided anony-
mously. The funds received from each Award are to be
used to cover expenses for any meeting sponsored by a
non-for-profit organization that is relevant to the goal of
translational medicine and research.
Twenty-two papers (9 self-nominated and 13 highly
accessed) from investigators representative of nine coun-
tries of four continents, covering a wide range of disci-
plines published in JTM between 1 July 2007–30 June
2008 were evaluated. For this purpose, an Award Com-
mittee* comprised of ten members of the Editorial Board
and one non-editorial board member selected and co-
chaired by Richard J. Ablin (University of Arizona College
of Medicine and the Arizona Cancer Center, Tucson, AZ)
and Pier Giorgio Natali ("Regina Elena", National Cancer
Institute, Rome, Italy) was formed. The National Institutes
of Health Scoring System of 1–5, with 1 = Outstanding
and 5 = Poor were used with the papers being evaluated
with regard to their:
￿ Scientific merit
￿ Originality
￿ Clarity
￿ Relevance to the purposes of translational medicine
and research (and in "The Bedside-to-Bench Award" to
direct study of human subjects)
￿ Research design
￿ Methodology
Excellence in Translational Medicine Award
Given the papers by Ying Jiang [3], Merck Research Labo-
ratories (West Point, PA) and Louise Rodino-Klapac [4],
Columbus Children's Research Institute (Columbus,
OH), and their respective co-workers were separated in
the evaluation by but "0.005" points, they were chosen
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co-recipients of the "Excellence in Translational Medicine
Award" for 2007–08.
With the necessity in drug development to make appro-
priate and cost effective "go" vs. "no go" decisions based
on safety, Jiang et al. [3] demonstrated the use of toxicog-
enomics for the diagnosis of drug-induced renal proximal
tubule toxicity. Their demonstration of the excellent diag-
nostic performance of the use of genes to identify changes
associated with drug-induced toxicities using renal proxi-
mal tubule injury as a paradigm provides a basis for the
potential translational application of toxicogenomics to
reduce the cost of drug development and improve the
attrition rates of new chemical entities in drug develop-
ment.
Corticosteriods, prolonging ambulation, provides a lim-
ited, at best treatment option for Duchenne muscular dys-
trophy (DMD). Multiple treatment options under
development include gene replacement therapy. In the
report by Rodino-Klapac et al. [4], co-recipient of the
"Excellence in Translational Award" for 2007–08, the
demonstration and applicability of the regional vascular
vs. muscular delivery of recombinant adeno-associated
viral vectors carrying a micro-dystrophin cDNA in mice
and non-human primates have been evaluated. The study
demonstrated, among other criteria, that a regional vascu-
lar delivery protects the host from widespread dissemina-
tion of virus, and fulfills the necessary criteria for gene
delivery with implications for potential clinical applica-
tion in children with DMD.
Bedside-to-Bench Award
Regulatory T cells (Tregs; CD4+CD25+Foxp3+), funda-
mental in maintaining tolerance to self-antigens, can
thwart T cell immunity to tumour-associated antigens and
thereby, represent a major obstacle to immunotherapy.
Thus, reducing their number or inhibiting their effector
functions intuitively has the potential of increasing the
efficacy of anti-tumour immunity. While increasing pre-
clinical data support this hypothesis, appropriate proof of
concept trials in man are yet to be demonstrated.
The contribution of Mary Ann Rasku et al. [5], Graham
Brown Cancer Center (Louisville, KY) selected as the
recipient of the "Bedside-to-Bench Award" for 2007–08,
has addressed this issue in metastatic cutaneous
melanoma. This investigator-initiated Phase II Clinical
Trial of metastatic melanoma, known for its resistance to
treatment, documented that transient depletion of Tregs
via administration of an IL-2 immunotoxin, which targets
the CD25 marker, is followed by the de novo appearance
of melanoma antigen-specific CD8+ T cells. By extensively
relying on the analysis of patient samples, the study by
Rasku et al. [5], represents a sound basis to address unan-
swered issues in this emerging basic and clinical research
area in animal models and man toward delineating, e.g.,
the relative effects of T cells and depletion of Tregs. In the
process, the paper by Rasku et al. [5] exemplifies the jour-
ney of "Translational Medicine" between laboratory and
the clinic and provides an excellent basis for further stud-
ies of T cell depleting agents and their efficacy in cancer
patients.
With congratulations to Ying Jiang [3], Louise Rodino-
Klapac [4] and Mary Ann Rasku [5] and co-workers, the
2nd "Excellence in Translational Medicine" and 1st "Bed-
side-to-Bench" Awards are now history. We are hopeful
these Awards will serve to encourage other investigators
devoted to improving the "bench-to-bedside" and "bed-
side-to-bench" concepts of translational medicine and
respective initiatives. Competition is now open for the
subsequent Awards in each of the two categories in which,
we very much look forward to the opportunity of selecting
next year's winning papers.
*"Excellence in Translational Medicine and Bedside-to-
Bench Awards Committee": Richard J. Ablin (Co-Chair-
man); Jean-Pierre Armand; Howard L. Kaufman; Bruce
Litman; Pier Giorgio Natali (Co-Chairman); Hideho
Okada; Michael Perricone; Rja K. Puri; Noriyuki Sato;
Patrick F. Terry and Craig Webb.
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